GGrantIndex
← Leaderboards

Stephen M Hahn

University Of Pennsylvania

Google Scholar ↗PubMed ↗ORCID ↗
$5,432,347
Attributed
$5,432,347
Total exposure
16
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.2M · FY2005–18
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$10,196,787 · 17

By mechanism

P01$5,774,068 · 4
U54$2,432,532 · 6
R01$1,158,417 · 1
R21$575,462 · 1
M01$256,308 · 5

Top collaborators

No co-investigators on record.

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasm Of Cervix Uteri”

Research focus

Malignant Neoplasm Of Cervix UteriHuman PapillomavirusBotswanaWomanProspectiveMalignant NeoplasmsClinical ResearchCohortResourcesResponseMonitorMentorsHuman SubjectGrantResearch StudyResearch PersonnelFamilyDesignHuman Therapy EvaluationProgramsNeoplasm /Cancer ChemotherapyNeoplasm /Cancer Radiation TherapyTumorClinical Trial Phase I

Grant awards (54)

Impact of immune reconstitution on outcomes to chemoradiation in cervical cancer$153,440
U54 · FY2018 · CA · contact PI
Factors Associated with HPV Screening and Acquisition in Young Women in Botswana$146,354
U54 · FY2018 · CA · contact PI
Shared Resources Core$122,972
U54 · FY2018 · CA · contact PI
Natural History & Pathogenesis of HPV in HIV infected women with cervical cancer$101,638
U54 · FY2018 · CA · contact PI
Biostatistics Core$74,840
U54 · FY2018 · CA · contact PI
Administrative Core$68,225
U54 · FY2018 · CA · contact PI
Impact of immune reconstitution on outcomes to chemoradiation in cervical cancer$152,862
U54 · FY2017 · CA · contact PI
Factors Associated with HPV Screening and Acquisition in Young Women in Botswana$145,008
U54 · FY2017 · CA · contact PI
Shared Resources Core$124,769
U54 · FY2017 · CA · contact PI
Natural History & Pathogenesis of HPV in HIV infected women with cervical cancer$102,439
U54 · FY2017 · CA · contact PI
Biostatistics Core$76,356
U54 · FY2017 · CA · contact PI
Administrative Core$69,915
U54 · FY2017 · CA · contact PI
Impact of immune reconstitution on outcomes to chemoradiation in cervical cancer$10,484
U54 · FY2016 · CA · contact PI
Factors Associated with HPV Screening and Acquisition in Young Women in Botswana$10,037
U54 · FY2016 · CA · contact PI
Shared Resources Core$8,836
U54 · FY2016 · CA · contact PI
Natural History & Pathogenesis of HPV in HIV infected women with cervical cancer$7,026
U54 · FY2016 · CA · contact PI
Biostatistics Core$5,237
U54 · FY2016 · CA · contact PI
Administrative Core$4,795
U54 · FY2016 · CA · contact PI
Impact of immune reconstitution on outcomes to chemoradiation in cervical cancer$156,799
U54 · FY2015 · CA · contact PI
Factors Associated with HPV Screening and Acquisition in Young Women in Botswana$150,119
U54 · FY2015 · CA · contact PI
Shared Resources Core$132,156
U54 · FY2015 · CA · contact PI
Natural History & Pathogenesis of HPV in HIV infected women with cervical cancer$105,075
U54 · FY2015 · CA · contact PI
Biostatistics Core$78,318
U54 · FY2015 · CA · contact PI
Administrative Core$71,711
U54 · FY2015 · CA · contact PI
Impact of immune reconstitution on outcomes to chemoradiation in cervical cancer$153,308
U54 · FY2014 · CA · contact PI
Shared Resources Core$125,211
U54 · FY2014 · CA · contact PI
Administrative Core$74,602
U54 · FY2014 · CA · contact PI
Enhancing Direct Tumor Cell Cytotoxicity By Manipulating Growth Factor Signaling$201,439
P01 · FY2012 · CA · contact PI
Enhancing Direct Tumor Cell Cytotoxicity By Manipulating Growth Factor Signaling$200,288
P01 · FY2011 · CA · contact PI
Enhancing Direct Tumor Cell Cytotoxicity By Manipulating Growth Factor Signaling$202,364
P01 · FY2010 · CA · contact PI
Enhancing Direct Tumor Cell Cytotoxicity By Manipulating Growth Factor Signaling$205,126
P01 · FY2009 · CA · contact PI
Enhancing Direct Tumor Cell Cytotoxicity By Manipulating Growth Factor Signaling$200,411
P01 · FY2008 · CA · contact PI
Molecular Targets for Drug and Radiation Sensitivity$1,326,588
P01 · FY2007 · CA · contact PI
Molecular Targets for Drug and Radiation Sensitivity$1,591,052
P01 · FY2006 · CA · contact PI
Molecular Targets for Drug and Radiation Sensitivity$1,585,979
P01 · FY2005 · CA
Clinical Trials of FTI Radiosensitization$386,139
R01 · FY2005 · CA
Molecular Targets for Drug and Radiation Sensitivity$260,821
P01 · FY2005 · CA
A CORRELATIVE TRIAL OF EF5, AN AGENT FOR THE DETECTION OF TUMOR HYPOXIA$2,045
M01 · FY2005 · RR
THE DETECTION OF TUMOR HYPOXIA AND VASCULARITY - IDT AND PDT$1,023
M01 · FY2005 · RR
TRIAL OF EF5, AN AGENT FOR DETECTING HYPOXIA$687
M01 · FY2005 · RR
Clinical Trials of FTI Radiosensitization$386,139
R01 · FY2004 · CA
A Correlative Trial of EF5, An Agent for the Detection of Tumor Hypoxia$2,485
M01 · FY2004 · RR
Trial of Ef5, an Agent for Detecting Hypoxia$1,776
M01 · FY2004 · RR
Clinical Trials of FTI Radiosensitization$386,139
R01 · FY2003 · CA
COMBINED MODALITY THERAPY WITH L-778,123 AND RADIOTHERAPY IN CANCER PATIENTS$124,146
M01 · FY2002 · RR
TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDT$0
P01 · FY2002 · CA
PHASE I TRIAL OF PDT IN PATIENTS WITH PROSTATE CARCINOMA$287,731
R21 · FY2001 · CA
COMBINED MODALITY THERAPY WITH L-778,123 AND RADIOTHERAPY IN CANCER PATIENTS$124,146
M01 · FY2001 · RR
TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDT$0
P01 · FY2001 · CA
COMBINED MODALITY THERAPY WITH L-778,123 AND RADIOTHERAPY IN CANCER PATIENTS$0
M01 · FY2001 · RR
PHASE I TRIAL OF PDT IN PATIENTS WITH PROSTATE CARCINOMA$287,731
R21 · FY2000 · CA
COMBINED MODALITY THERAPY WITH L-778,123 AND RADIOTHERAPY IN CANCER PATIENTS$0
M01 · FY2000 · RR
COMBINED MODALITY THERAPY WITH L-778,123 AND RADIOTHERAPY IN CANCER PATIENTS$0
M01 · FY2000 · RR
COMBINED MODALITY THERAPY WITH L-778,123 AND RADIOTHERAPY IN CANCER PATIENTS$0
M01 · FY2000 · RR